N-Monoacetylcystine

N-Monoacetylcystine

SCHEMBL468824

CC(=O)NC(CSSCC(N)C(=O)O)C(=O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
THRB P10828 1/20 0.48
ALOX15 P16050 1/20 0.48
NFKB1 P19838 1/20 0.48
PTGS2 P35354 1/20 0.48
THPO P40225 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ALDH1A1 P00352 2/20 0.47
NOS2 P35228 4/20 0.42
NOS1 P29475 3/20 0.42
NOS3 P29474 2/20 0.42
ITGB1 P05556 2/20 0.41
ITGA4 P13612 2/20 0.41
MEN1 O00255 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
GNPAT O15228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
N-Monoacetylcystine SCHEMBL468826 1.00 MAPT (0.48) MAPTKDM4ETHRBALOX15NFKB1
N-Monoacetylcystine SCHEMBL20816351 1.00 MAPT (0.48) MAPTKDM4ETHRBALOX15NFKB1
N-Monoacetylcystine SCHEMBL29438781 1.00 MAPT (0.48) MAPTKDM4ETHRBALOX15NFKB1
N-Monoacetylcystine SCHEMBL111494 1.00 MAPT (0.48) MAPTKDM4ETHRBALOX15NFKB1
N-Monoacetylcystine SCHEMBL6368208 0.98 MAPT (0.47) MAPTKDM4ETHRBALOX15NFKB1
N-Monoacetylcystine SCHEMBL31253425 0.98 MAPT (0.47) MAPTKDM4ETHRBALOX15NFKB1
N-Monoacetylcystine SCHEMBL6368194 0.98 MAPT (0.47) MAPTKDM4ETHRBALOX15NFKB1
N-Monoacetylcystine SCHEMBL26134149 0.97 MAPT (0.50) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL20839964 0.90 MAPT (0.46) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL17749411 0.90 NOS2 (0.44) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600953-B2 Compositions and method for establishing organoid cultures from cryogenically preserved tissue THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2026-04-14 US claimed
US-12351678-B2 Process for preparing stabilized aliphatic polyester, and compositions obtained therewith TOTALENERGIES CORBION B.V. (NL) 2025-07-08 US claimed
CN-119156343-A Peptide-carrying carrier system and use thereof 周美吟 2024-12-17 CN claimed
EP-4438014-A2 IMPROVING PULMONARY AIRFLOW Apreo Health, Inc. (US) 2024-10-02 EP claimed
EP-4172275-B1 TIO2-FREE PIGMENT SUN CHEMICAL CORP (US) 2024-02-07 EP claimed
EP-3976705-B1 PROCESS FOR PREPARING STABILIZED ALIPHATIC POLYESTER, AND COMPOSITIONS OBTAINED THEREWITH TOTALENERGIES CORBION B V (NL) 2024-01-10 EP claimed
CN-113906080-B Method for preparing stabilized aliphatic polyesters and compositions obtained therewith 道达尔科尔比翁聚乳酸私人有限公司 2023-12-12 CN claimed
CN-114563495-B Detection method of acetylcysteine and related substances thereof 杭州民生药业股份有限公司 2023-09-15 CN claimed
CN-115094041-B Stomach cancer organoid culture medium and culture method 杭州艾名医学科技有限公司 2022-12-09 CN claimed
US-11459341-B1 Organic anion lithium ionic cocrystal compounds and compositions UNIVERSITY OF SOUTH FLORIDA (US) 2022-10-04 US claimed
EP-1143925-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2001-10-17 EP claimed
US-6162447-A Microstructured compositions CIBA SPECIALTY CHEMICALS CORPORATION (US) 2000-12-19 US claimed
US-6159352-A Process for the electrochemical synthesis of N-acetylcysteine from cystine UNIVERSIDAD DE ALICANTE (ES) 2000-12-12 US claimed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 WO claimed
WO-2000040217-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-07-13 WO claimed
EP-0905282-B1 PROCESS FOR THE ELECTROCHEMICAL SYNTHESIS OF N-ACETYLCYSTEINE FROM CYSTINE UNIV ALICANTE (ES) 2000-01-26 EP claimed
EP-0905282-A1 PROCESS FOR THE ELECTROCHEMICAL SYNTHESIS OF N-ACETYLCYSTEINE FROM CYSTINE UNIVERSIDAD DE ALICANTE (ES) 1999-03-31 EP claimed
EP-0875244-A2 Cosmetically accceptable microstructured compositions Ciba SC Holding AG (CH) 1998-11-04 EP claimed
EP-0538193-B1 Condensed cycloaliphatir-amidino-hydrazon salts as S-adenosylmethionin decarboxylase inhibitors CIBA GEIGY AG (CH) 1996-12-04 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600953-B2 Compositions and method for establishing organoid cultures from cryogenically preserved tissue BMP4, DSP, WNT3A MAPT 3267/4885KDM4E 872/4885THRB 464/4885
US-11459341-B1 Organic anion lithium ionic cocrystal compounds and compositions SLC10A6, MLX, LPXN MAPT 160/4885KDM4E 3655/4885THRB 3474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.